<DOC>
	<DOCNO>NCT00312026</DOCNO>
	<brief_summary>This Phase IV randomize , double-blind , placebo-controlled study evaluate safety efficacy SC efalizumab adult patient ( 18 year age old ) chronic moderate severe plaque psoriasis involve hand and/or foot previous exposure efalizumab . The study consist screening period , treatment period , observation period .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Efalizumab Adult Patients With Plaque Psoriasis Involving Hands and/or Feet</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Provide write informed consent Health Insurance Portability Accountability Act 1996 ( HIPAA ) document Be age 18 year old Have chronic ( 6 month great ) moderate severe plaque psoriasis involve hand and/or foot without pustule without psoriasis site Have PGA rating moderate ( 3 ) severe ( 4 ) hand and/or foot psoriasis Be candidate systemic therapy opinion investigator Be naive efalizumab treatment Weigh 125 kg For woman childbearing potential , use method contraception acceptable investigator prevent pregnancy agree continue practice acceptable method contraception duration participation study 6 week last dose efalizumab Have history hypersensitivity efalizumab component Are use exclude therapy Have history ongoing alcohol illegal drug abuse Have history ongoing uncontrolled serious bacterial , viral , fungal , atypical mycobacterial infection . This include diagnosis require 2 week therapy , endocarditis osteomyelitis , treat past 6 month . In addition , patient currently receive antibiotic , antiviral , antifungal infection suppression prophylaxis diagnosis , patient exclude . Have history opportunistic infection ( e.g. , systemic fungal infection , parasite ) Are seropositive hepatitis B antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) . Patients undergo test screening , patient seropositive hepatitis B antigen , hepatitis C antibody , HIV exclude . Have history active tuberculosis currently undergo treatment tuberculosis . A purified protein derivative ( PPD ) test chest xray perform screening visit . Patients positive PPD test ( due BCG vaccination ) chest xray exclude . Have presence history malignancy within past 5 year , include lymphoproliferative disorder . Patients history fully resolve basal squamous cell skin cancer may enrol . Are pregnant lactate woman Have diagnosis hepatic cirrhosis , regardless cause severity Have history thrombocytopenia Have history hemolytic anemia Have history clinically significant anemia Have WBC count &lt; 4,000 cells/uL &gt; 14,000 cells/uL Have hematocrit ( HCT ) &lt; 30 % hemoglobin ( Hgb ) level &lt; 11 g/dL Have platelet count &lt; 150,000 cells/uL Have hepatic enzyme level ≥3 time upper limit normal Have serum creatinine level ≥2 time upper limit normal Have expose experimental drug treatment within 30 day 5 halflives , whichever longer , prior screen visit Have previous exposure efalizumab Have vaccinate live virus live bacteria within 14 day prior first dose efalizumab Have medical condition , judgment investigator , would jeopardize patient 's safety follow exposure study drug ( efalizumab placebo equivalent ) would significantly interfere patient 's ability comply provision protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Hands</keyword>
	<keyword>Feet</keyword>
	<keyword>Hand</keyword>
</DOC>